Skin and Connective Tissue DiseasesSkincAIrNCT07506967
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
A study testing A mobile app with AI functionality for diagnosing skin-related NTDs in people with Skin and Connective Tissue Diseases and Neglected Tropical Diseases, run by Kenya Medical Research Institute at 5 sites in 5 countries.
Trial summary
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making… Read more about this study
- Who is it for?
- Ages 0 years and older
- Conditions the study is for
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy
- What is being tested?
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,420 participants
- Where
- 5 sitesin 5 countries
- Study dates
- 1 May 2026to 31 May 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Professional Role:
- o Must be working as a FHW at one of the selected health centers at the time of the validation study.
- Justification: The study aims to assess the diagnostic performance of those directly involved in primary patient care in the targeted settings.
- Willingness to Participate:
- o Willing to provide written informed consent to participate in the study.
- Justification: Ethical standards require voluntary participation with informed consent.
Show all 21Show fewer
- Smartphone Usage:
- o Willing and able to use a smartphone during the study.
- Justification: The SkincAIr app is smartphone-based; therefore, FHWs must be willing to use and have access to such devices.
- No Specialized Dermatology Training:
- FHWs without specialised training in dermatology or extensive experience in skin disease diagnosis.
- Justification: The study aims to evaluate the app's effectiveness among generalist healthcare workers who would benefit most from diagnostic support tools.
- 1. Presenting with Skin Complaints:
- o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition.
- Justification: The study aims to evaluate the app's effectiveness in real-world conditions, including all patients with potential skin-NTDs 2. Willingness to Participate: o Patients (or guardians, in the case of minors) willing to provide written informed consent for participation.
- Justification: Ethical standards require informed consent from patients or their legal guardians.
- 3. Ability to Comply with Study Procedures:
- o Patients are able to follow study instructions and attend necessary follow-up appointments.
- Justification: Ensures complete data collection and accurate assessment of outcomes.
- 4. Patients with Co-morbid conditions:
- Justification: Immunosuppression that occurs in some comorbid conditions e.g. HIV/AIDS or severe malnutrition can reveal the Skin disease and can affect both the clinical progression and even severity of the Skin NTD. This also includes patients with multiple skin-NTDs.
Who cannot join
- 1. Prior Specialised Training in dermatology:
- o FHWs with formal education or extensive experience in dermatology.
- Justification: Including specialists could skew results, as their baseline diagnostic accuracy may already be high, reducing the observable impact of the app.
- 2. Refusal or Inability to Consent:
- FHWs unwilling or unable to provide written informed consent.
- Justification: Ethical compliance requires informed consent for participation. 3. Inability to Use the App: o FHWs unable to use a smartphone due to technical limitations, physical impairments, or lack of familiarity with the technology.
Show all 32Show fewer
- Justification: Effective use of the app is essential for the intervention; inability to use it would prevent meaningful participation.
- Patients with Skin complaints Size
- ● Total Patients: ~750 patients Age Group
- ● All Age Groups:
- o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan.
- Sex Distribution
- Male and Female Patients
- Justification: Both sexes are included to capture the full spectrum of the disease burden and ensure the app's diagnostic accuracy is effective regardless of sex.
- Refusal or Inability to Consent:
- o Patients (or guardians) unwilling or unable to provide written informed consent.
- Justification: Ethical compliance requires informed consent for participation.
- Non-Skin-Related Complaints:
- o Patients presenting with complaints unrelated to skin conditions.
- Justification: The study focuses on skin-NTDs; including unrelated cases would not contribute to the study objectives.
- Previous Participation in the Study:
- o Patients who have already participated in the study.
- Justification: To avoid duplicate data and potential bias in outcomes.
- Additional Considerations:
- Diversity and Representation ● Geographical Diversity:
- o Including health centres from different regions within each country ensures that the findings are representative of various settings (urban, peri-urban, rural).
- ● Cultural and Socioeconomic Factors:
- o The study acknowledges that cultural beliefs and socioeconomic status may influence healthcare-seeking behaviour and disease presentation. By including a diverse patient population, the study aims to capture these variations.
- Ethical Justification ● Inclusivity:
- Including all age groups and both sexes aligns with ethical principles of justice and fairness, ensuring that the benefits of the research are accessible to all segments of the population.
- Vulnerable Populations:
- While including minors and potentially vulnerable adults, the study will implement additional safeguards to protect their rights and well-being, following ethical guidelines and obtaining consent from guardians when necessary.
Trial locations and contacts
5 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
5 sites in 5 countries
Democratic Republic of the Congo1 site
Université Catholique de Bukavu (UCB)
Bukavu, South Kivu
Patrick de Marie Katoto Cimusa, PhD, 243000000000, katoto.patrick@ucbukavu.ac.cd
Samuel Makali Lwamushi, 243000000000, makali.lwamushi@ucbukavu.ac.cd
Ethiopia1 site
Armauer Hansen Research Institute (AHRI)
Addis Ababa, Addis Ababa
Kassa Haile, MD, 251111266385, kassa.haile@ahri.gov.et
Amanuel Lulu, 251111266385, amanuel.lulu@ahri.gov.et
Kenya1 site
Kenya Medical Research Institute (KEMRI)
Kisumu, Nyanza
Maurice Odiere, PhD, 254721845777, Modiere@kemri.go.ke
Ruth Nyangacha, 254728710650, RNyangacha@kemri.go.ke
Nigeria1 site
Leprosy and Tuberculosis Relief Initiative Nigeria (LTR)
Jos, Plateau State
Tahir Dahiru, PhD, 2348036000000, tahirdahiru@ltrnigeria.org
Shehu Yusuf, 2348036000000, tdahiru@ltrinigeria.org
Senegal1 site
Centre Hospitalier de l'Ordre de Malte (CHOM)
Dakar, Dakar
Lahla Fall, MD, 221773328705, hopitalsenegal@ordredemaltefrance.org
Lahla Fall, MD
About this study
Official title: Early Detection and Management of SKIN-related negleCted Tropical Diseases Using Artificial Intelligence in Sub-saharan afRica (SkincAIr)
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making diagnosis difficult. To address this challenge, the SkincAIr project is testing whether a mobile app powered by artificial intelligence (AI) can help FHWs improve their ability to detect Skin NTDs. The study will be conducted in two arms. In the first clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions that will be used for development and training of the AI model within the SkincAIr app before it is tested among FHWs. The second validation study arm will take place in 3 countries (Kenya, Ethiopia and Senegal), and will involve 50 FHWs and around 750 patients in each country over 24 months. During the first 12 months (Phase A), FHWs will diagnose patients using standard methods without the app, establishing baseline performance on key indicators including diagnostic accuracy, time to diagnosis, referral patterns, and cost implications of improved primary-level diagnosis. For the following 6 months (Phase B), FHWs will use the SkincAIr app with AI functionality activated to support diagnosis and enable real-time geolocated disease mapping and hotspot identification. In the final 6 months (Phase C), the app is withdrawn to assess whether FHWs retain their improved diagnostic skills. We will summarize the results using simple numbers and charts to show how often things happen and what the average results look like. Researchers will evaluate how well the app improves diagnosis by FHWs and whether FHWs retain their improved skills even after AI support is removed, by comparing their results with those of a skin specialist (dermatologist). Interviews and group discussions will be recorded, written down, organized into key ideas, and carefully reviewed using a computer program to understand the main themes. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to relevant institutional and regulatory authorities. If successful, this AI tool could boost early detection of skin diseases, enhance disease tracking, and improve healthcare in underserved areas.
Read the detailed description
ABSTRACT:
Skin-related Neglected Tropical Diseases (Skin NTDs) pose a significant public health challenge, affecting 1.8 billion people globally. Skin NTDs significantly affect marginalized communities due to several factors, such as lack of trained healthcare staff and diagnostic tools. Currently, due to a scarcity of dermatologists, the majority of the rural population with skin diseases is served by frontline health workers (FHWs) with limited dermatological knowledge. The low prevalence of skin NTDs further confounds their diagnosis and recognition by FHWs. Novel innovative approaches are therefore needed to build capacity and improve diagnosis for skin NTDs. Mobile health (mHealth) interventions, particularly those incorporating artificial intelligence (AI), offer a promising solution to enhance the diagnostic capabilities of FHWs. The SkincAIr project aims to evaluate whether introducing a mobile app with AI functionality can improve the diagnostic accuracy (sensitivity and specificity) of FHWs in detecting skin NTDs, and to determine their retention of improved diagnostic skills after the AI assistance is removed, indicating potential capacity building and sustained improvement in healthcare delivery. In the clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions (Image data collection phase) that will be used for training and development of the SkincAIr app, before it is evaluated among FHWs during the 24-month validation study. The validation study arm for the app will involve a within-subjects longitudinal design which will enroll 50 FHWs and will recruit about 750 patients with skin complaints from areas with high burden of skin NTDs in each of 3 countries (Kenya, Ethiopia, Senegal) over a 24-month validation study period. Data will be analyzed using R and Python, with descriptive statistics (frequency, central tendency, and dispersion) summarized in tables and charts. Diagnostic accuracy of FHWs before and after app introduction will be evaluated using sensitivity, specificity, predictive values, and percent agreement with a dermatologist. Qualitative data from interviews and FGDs will be audio-recorded, transcribed, coded, and thematically analyzed using Atlas.ti Version 7. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to IRBs and regulatory authorities. It is envisaged that the app will improve the diagnostic accuracy of FHWs in early detection of skin NTDs and will facilitate real-time epidemiological surveillance, contributing to improved disease mapping and hotspot identification.
INTRODUCTION/BACKGROUND:
Skin-related Neglected Tropical Diseases (MDPI, 2019) (skin NTDs) such as leprosy, Buruli ulcer, yaws (endemic treponematosis), cutaneous leishmaniasis, chromoblastomycosis, mycetoma, scabies, tungiasis, Post Kala-azar Dermal Leishmaniasis (PKDL), lymphatic filariasis, onchocerciasis, podoconiosis and sporotrichosis pose a significant public health challenge, affecting 1.8 billion people globally at any given moment (WHO, 2023). Particularly in sub-Saharan Africa (SSA), these diseases are highly prevalent and are linked to substantial health inequities, predominantly impacting marginalized communities (Kariuki et al. 2023). Kenya for instance has a significant burden of Skin NTDs, including Lymphatic filariasis at the Coastal region (Njenga et al. 2017; Ofire et al. 2025), Mycetoma in Turkana (Colom et al. 2023), Leishmaniasis in Rift Valley and Eastern parts (Baringo, Naivasha/Gilgil, Laikipia, Samburu, Nakuru, Meru, West Pokot, Elgeyo Marakwet, Isiolo, Nyandarua, and Marsabit) (Ngere et al. 2020; van Dijk et al. 2024), Tungiasis (Elson et al. 2019; Nyangacha et al. 2019) and Scabies (Schmeller and Dzikus, 2001; Mbogori 2014; Macharia et al. 2024) that have a wide distribution across the country and some pockets of cases of Leprosy in Kwale, Kilifi, Kisumu, Siaya, Homabay and Busia counties (Kenya NTLLD Program Annual Report, 2014; Wangara et al. 2019).
The prevalence of these diseases is exacerbated by factors such as poverty and a lack of adequate healthcare resources, notably insufficiently trained staff for effective management of skin NTDs (Ochola et al. 2021). The stigma surrounding skin NTDs, entrenched in societal and economic contexts, leads to isolation and discrimination, discouraging diagnosis or treatment, which in turn exacerbates disease spread and complicates control and elimination efforts, creating a self-perpetuating cycle of challenges. A high proportion of NTDs have major skin manifestations. Therefore, examination of the skin serves as an opportunity to identify multiple NTDs in a single intervention. The integrative approach, recommended by the World Health Organization (WHO) (https://www.who.int/activities/promoting-the-integrated-approach-to-skin-related-neglected-tropical-diseases), results in enhanced case detection and increased efficiency through sharing of resources and expanded programme coverage. However, there is a major barrier to the integration of skin NTD interventions: the lack of dermatologists (Schmid-Grendelmeier et al. 2019) (one dermatologist for 1-2 million inhabitants) and adequately trained healthcare staff. Currently, the majority of the rural population with skin diseases is served by frontline health workers (FHWs) with limited dermatological knowledge (Mieras et al. 2018). This challenge is further confounded by the low prevalence of skin-related NTDs, which makes them difficult to be recognized by FHWs (Mieras et al. 2018; Hotez et al. 2009). As skin NTDs rely mostly on clinical diagnosis, lack of adequate training of FHWs jeopardizes disease control programs and the attainment of the overall 2021-2030 WHO NTD roadmap target to reduce morbidity, disability and the psychosocial impact of skin NTDs by 2030. Novel innovative approaches are needed to build capacity and improve diagnosis for skin NTDs to realize the 2030 goals. In this regard, Artificial Intelligence (AI) now provides an unprecedented opportunity to use advances in medical imaging applied to the skin to tackle current barriers in the diagnosis and management of skin NTDs in SSA.
Existing AI models in dermatology often focus on diseases prevalent in developed countries and rely on homogeneous datasets, leading to models that do not generalize well to diverse populations. They typically use internal validation methods, which are insufficient for real-world deployment where models encounter varied data sources (Daneshjou et al. 2021). Whereas AI-powered algorithms have demonstrated diagnostic accuracy similar to expert clinicians in high-resource settings (Salinas et al. 2024), very few studies have explored the use of AI-powered apps for diagnosing skin NTDs in low-resource settings in SSA. This is due to the novelty of the technology which contributes to the scarcity of such research. The WHO NTD-led Global Initiative discusses progress, challenges, gaps and solutions in developing and implementing artificial augmented intelligence-based apps as a capacity building and monitoring tool for skin NTDs and selected common skin conditions in resource-limited settings. Recently, the WHO incorporated two online AI algorithms that intend to classify 12 skin NTDS and 24 common skin conditions (Quilter et al. 2024) into the WHO Skin NTDs app (mainly built as a repository of educational resources and training materials, which adhere to WHO guidelines). While the app aims to improve capacity building through AI, its "real-world" impact on disease management is still not available and upcoming studies will determine its utility. The performance of AI-algorithms is also limited by the availability of images datasets. In the AI4Leprosy study conducted in 2022 at the Brazil leprosy national referral center, although the convolutional neural networks (CNN)-based AI algorithm could contribute to the diagnosis of leprosy with high classification accuracy (90%) (AI4Leprosy), to the best of our knowledge, this has not been validated in a low-resource setting with lack of highly specialized staff. Further afield, while the technology's performance is increasingly being validated in dermatological conditions such as melanoma and other skin cancers (Patel et al. 2023), the direct evidence for its efficacy in diagnosing skin-NTDs remains limited. Overall, while these studies and initiatives demonstrate the potential of AI-powered diagnostic tools, evidence specific to their use for skin NTDs in low-resource settings is still emerging.
Our proposed validation study aims to address the aforementioned gaps by evaluating the diagnostic accuracy of an AI-powered app in diagnosing skin NTDs in Kenya, Ethiopia and Senegal, providing critical insights into its practical utility and impact on clinical practice in these settings. The intervention is the SkincAIr Research App, a unified mobile platform containing three role-specific modules: a Dermatologist Dataset eCRF for structured image collection by dermatologists across 5 countries; an FHW eCRF for clinical data collection and case documentation across all 3 study phases; and the SkincAIr Detection App - an AI-powered diagnostic decision-support feature embedded within the FHW eCRF, activated exclusively during Phase B (6 months), and withdrawn during Phase C to assess retention of improved diagnostic skills. The study measures: (SO1) diagnostic performance of FHWs with and without the app, including early detection rate, diagnostic accuracy, sensitivity and specificity against a dermatologist reference standard; (SO2) dataset quality including number, geographic diversity and image quality; (SO3) reduction in diagnostic delay; (SO4) epidemiological surveillance indicators including DHIS2 integration, case confirmation ratio and hotspot identification; (SO5) FHW knowledge gain and user satisfaction. Cost-effectiveness is assessed through primary vs secondary care cost comparison and ICER calculation.
This clinical study will provide vital data to assess the practical utility of AI in improving diagnostic accuracy and speed among non-specialist health workers. By leveraging AI and mobile technology, we can equip FHWs in low-resource settings with tools to quickly detect and manage skin NTDs.
Justification for the Study:
Neglected tropical diseases (NTDs) affect over one billion people globally, with skin NTDs such as leprosy, cutaneous leishmaniasis, and onchocerciasis contributing significantly to morbidity, disability, and stigma in affected populations. Early detection and treatment are crucial to prevent complications, reduce transmission, and improve patient outcomes. In resource-limited settings like Kenya, Ethiopia, Senegal, Nigeria and the Democratic Republic of the Congo, FHWs are often the first point of contact for patients with skin conditions. However, FHWs typically lack specialized training in dermatology, leading to misdiagnosis or delayed diagnosis of skin NTDs. Mobile health (mHealth) interventions, particularly those incorporating AI, offer a promising solution to enhance the diagnostic capabilities of FHWs. The SkincAIr project aims to evaluate whether introducing a mobile app with AI functionality can improve the diagnostic accuracy of FHWs in detecting skin NTDs. Additionally, the study seeks to determine if FHWs retain improved diagnostic skills after the AI assistance is removed, indicating potential capacity building and sustained improvement in healthcare delivery. Our project transcends the twin limitations of lack of specialized training in dermatology and availability of images datasets by collecting real clinical data from multiple geographic locations within Low-and Middle-Income Countries (LMICs), ensuring that our models are trained and externally validated on diverse datasets representative of the target populations. Inclusion of Kenya, Ethiopia, Senegal, Nigeria and the Democratic Republic of the Congo will contribute to the diversity of images that are representative of the Skin NTDs endemic in multiple geographic locations in sub-Saharan Africa. As these locations present unique challenges, including limited healthcare infrastructure and varying disease presentations, the proposed study is crucial in bridging this gap. We will implement a controlled image acquisition protocol to standardize data collection, minimizing the risk of shortcut learning - where models might rely on irrelevant features due to spurious correlations (Winkler et al. 2019). By integrating multimodal data, including clinical parameters, and ensuring robustness to missing data, our models will offer more accurate and personalized diagnostic and predictive capabilities.
Null Hypothesis:
The use of the SkincAIr AI-powered mobile application will not improve the diagnostic accuracy (sensitivity and specificity) of FHWs in detecting skin-NTDs compared to their baseline performance without the app.
General Objective:
To develop an AI supported diagnostic tool for skin NTDs (SkincAIr) and test its performance and impact among frontline health workers (FHWs) in detecting select skin NTDs.
Specific Objectives:
- To collect image data for skin NTDs and other skin conditions by dermatologists/dermatology officers or other officers trained on skin NTDS to be used in the training and development of the SkincAIr app.
- To quantify the impact of the SkincAIr mobile application on the diagnostic accuracy (sensitivity and specificity) of frontline health workers (FHWs) in identifying skin-neglected tropical diseases (skin-NTDs) and other skin conditions.
- To measure the impact of SkincAIr-assisted diagnosis on key clinical and operational metrics:
- Time to diagnosis from first visit - How long it takes for a patient to receive a diagnosis, from the time they first present to a healthcare provider
- Time from initial presentation to definitive diagnosis - the time from any initial contact (perhaps community level or first clinic) to the final confirmed diagnosis by a specialist
- Reduction in treatment initiation delays
- Changes in referral patterns to specialized centers - Changes in how often and how appropriately patients are referred to specialists or higher centers
- Cost savings in secondary care attributable to enhanced primary diagnosis (early and accurate diagnoses by FHWs)
- New hotspots of suspected or confirmed skin NTDs during the project period (up to M60).
- To evaluate the sustainability of improved diagnostic skills among FHWs following the withdrawal of AI assistance.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer, Cutaneous Leishmaniasis, Scabies
- Being tested
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Keywords
- Skin-related neglected tropical diseases, Artificial Intelligence, Mobile Health, mHealth, Frontline Health Workers, Diagnostic Accuracy, Sub-Saharan Africa, Skin NTDs, Digital Health, AI Diagnostic Tool, Capacity Building, Kenya, Ethiopia, Senegal, Nigeria, Democratic Republic of the Congo
- Medical subject headings
- Skin and Connective Tissue Diseases, Neglected Diseases, Leprosy, Buruli Ulcer, Leishmaniasis, Cutaneous, Scabies, Mycetoma, Elephantiasis, Filarial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A mobile app with AI functionality for diagnosing skin-related NTDsDevice
Also called SkincAIr Detection App
The SkincAIr Research App is a unified mobile platform (Android, offline-capable) containing three role-specific modules: (1) Dermatologist Dataset eCRF - used by dermatologists in 5 countries (M12-M48) to capture and annotate high-quality clinical images of skin NTDs for AI model development; (2) FHW eCRF - used by frontline health workers (FHWs) in 3 countries (M22-M45) to document clinical assessments with and without AI support; (3) SkincAIr Detection App - an AI-powered diagnostic decision-support feature embedded within the FHW eCRF, activated exclusively during Phase B (6 months), providing image-based diagnostic suggestions to assist FHWs in identifying skin NTDs. The SkincAIr Detection App is the primary intervention under validation. If proven effective, it is intended for adoption by National Ministries of Health, integration into national Health Information Systems (DHIS2), and scale-up across sub-Saharan Africa.
| Study group | Role | What they receive |
|---|---|---|
| Clinical Image Data Collection | Other | Dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Nigeria and DRC) use the Dermatologist Dataset eCRF module of the SkincAIr Research App to capture and annotate high-quality clinical images of skin NTDs and other skin conditions during routine clinical activity (M12-M48, 36 months). Structured metadata including disease type, body site, age group, severity and geographic location are recorded alongside each image. Collected images are used exclusively to train and develop the SkincAIr AI model prior to its validation among frontline health workers. Target: >3,500 high-quality annotated images of skin NTDs across 11 disease categories in 5 countries (KPI 2.1). Receives: Device: A mobile app with AI functionality for diagnosing skin-related NTDs |
| SkincAIr Validation Study - Frontline Health Workers | Experimental | 50 frontline health workers (FHWs) per country (Kenya, Ethiopia, Senegal) and ~750 patients with skin complaints per country participate in a 24-month within-subjects validation study using the SkincAIr Research App. FHWs complete 3 consecutive phases: Phase A (M22-M33, 12 months): baseline data collection using standard diagnostic methods without AI support, using the FHW eCRF only; Phase B (M34-M39, 6 months): AI-assisted diagnosis using the SkincAIr Detection App embedded in the FHW eCRF, activated exclusively during this phase; Phase C (M40-M45, 6 months): AI support withdrawn to assess retention of improved diagnostic skills. Each FHW serves as their own control. A reference dermatologist independently evaluates each patient to provide the gold standard diagnosis. Receives: Device: A mobile app with AI functionality for diagnosing skin-related NTDs |
What is being measured
The primary outcome is the main question the study is designed to answer.
FHW Diagnostic Accuracy Improvement (FHW-DAI)
Percentage improvement in diagnostic accuracy of frontline health workers (FHWs) when using the SkincAIr Detection App compared to baseline performance without the app. Diagnostic accuracy is measured by comparing FHW diagnoses against the reference standard diagnosis established independently by a co-located dermatologist for each patient case. A minimum improvement of 15% (KPI 1.3) is required to demonstrate clinical utility of the app. Measured across all 3 study phases: Phase A (baseline, no app, M22-M33); Phase B (app active, M34-M39); Phase C (app withdrawn, M40-M45).
Measured: Month 22 through Month 45
Secondary outcomes (12)
Early Detection Rate of Skin NTDs by FHWs (KPI 1.1)
Percentage increase in early-stage skin NTD case detection by frontline health workers (FHWs) compared to baseline. Early detection is defined as FHW identification of a skin NTD case at an early disease stage, confirmed by the reference dermatologist. A minimum increase of 12% at 6 months of app use (Phase B) is required (KPI 1.1). Measured by comparing the proportion of early-stage confirmed cases detected by FHWs across Phase A (baseline) and Phase B (app active).
Measured: 22 through Month 39
Time Reduction from FHW Suspicion to Diagnostic Confirmation (KPI 1.2)
Reduction in time (days) from the moment a FHW suspects a skin NTD to external diagnostic confirmation by a dermatologist. A reduction of more than 10% compared to baseline (Phase A) is required (KPI 1.2). Measured using timestamps recorded in the FHW eCRF across all 3 study phases.
Measured: Month 22 through Month 45
Sensitivity of FHW Diagnosis for Skin NTDs (KPI 1.4)
True Positive Rate of FHW diagnoses for skin NTDs, defined as the proportion of confirmed skin NTD cases correctly identified by FHWs. A minimum sensitivity of 80% for at least 7 skin NTD categories is required (KPI 1.4). Measured by comparing FHW diagnoses against the dermatologist reference standard across all study phases.
Measured: Month 22 through Month 45
Specificity of FHW Diagnosis for Skin NTDs (KPI 1.5)
True Negative Rate of FHW diagnoses for skin NTDs, defined as the proportion of non-skin NTD cases correctly excluded by FHWs. A minimum specificity of 80% for at least 7 skin NTD categories is required (KPI 1.5). Measured by comparing FHW diagnoses against the dermatologist reference standard across all study phases.
Measured: Month 22 through Month 45
Diagnostic Delay Reduction from First Healthcare Contact to Confirmation (KPI 3.1)
Reduction in total time (days) from a patient's first healthcare contact to external diagnostic confirmation by a dermatologist. A reduction of more than 10% compared to baseline is required (KPI 3.1). This KPI measures end-to-end diagnostic pathway efficiency and complements KPI 1.2 by capturing the full patient journey including community-level contacts prior to FHW encounter.
Measured: Month 22 through Month 45
FHW Diagnostic Knowledge Gain and Retention (KPI 5.1)
Percentage improvement in FHW diagnostic knowledge scores measured using standardised image-based clinical vignette assessments administered at 3 timepoints: pre-AI exposure (end of Phase A), post-AI exposure (end of Phase B), and post-withdrawal (end of Phase C). A minimum knowledge gain of 70% is required (KPI 5.1). This outcome also assesses whether knowledge is retained after AI support is withdrawn (Phase C).
Measured: Month 33 through Month 45
User Education Satisfaction Index (UESI) (KPI 5.2)
FHW satisfaction with the SkincAIr Detection App educational features, measured using a structured satisfaction questionnaire administered at the end of Phase B. Satisfaction is scored on a standardised scale. A minimum satisfaction index of 90% is required (KPI 5.2). Data collected via self-administered questionnaire within the SkincAIr Research App.
Measured: Month 34 through Month 39
Epidemiological Surveillance - Subjects Integrated into DHIS2 (KPI 4.1)
Cumulative number of unique subjects whose data from the SkincAIr ecosystem - including validation study eCRF records and routine app usage - are integrated into national Health Information Systems (DHIS2) by end of project. A minimum of 10,000 unique subjects integrated is required (KPI 4.1). Measured through system logs and DHIS2 integration records.
Measured: Month 22 through Month 60
Case Confirmation Ratio (CCR) (KPI 4.2)
Proportion of skin NTD cases suspected by FHWs that are subsequently confirmed by a dermatologist or laboratory test. A minimum Case Confirmation Ratio of 50% is required (KPI 4.2). This indicator measures the clinical relevance and accuracy of FHW case identification within the surveillance system.
Measured: Month 22 through Month 45
Response Time to Hotspot Identification (KPI 4.3)
Time between identification of a skin NTD hotspot by the SkincAIr system and acknowledgement by the relevant health authority. A reduction of more than 10% in response time compared to baseline is required (KPI 4.3). Measured using notification and acknowledgement timestamps from SkincAIr system logs and email records.
Measured: Month 22 through Month 60
New Skin NTD Hotspots Identified (KPI 4.4)
Number of new geographically distinct skin NTD hotspots identified through the SkincAIr surveillance system during the project period. A hotspot is defined as a spatio-temporal cluster of cases exceeding baseline levels in a defined geographic grid (5-10 km resolution). A minimum of 5 new hotspots identified is required (KPI 4.4).
Measured: Month 12 through Month 60
Cost-Effectiveness of AI-Assisted Primary Diagnosis
Cost savings achieved by shifting appropriate skin NTD case management from secondary to primary care level through improved FHW diagnostic accuracy. Measured by comparing direct and indirect costs per case at primary vs secondary care level across Phase A (baseline) and Phase B (app active). Includes calculation of the Incremental Cost-Effectiveness Ratio (ICER) to assess value for money of the SkincAIr intervention.
Measured: Month 22 through Month 45
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2026
- Study start1 May 2026 (estimated)
- Primary completion28 Feb 2029 (estimated)
- Study completion31 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (30)Papers the sponsor has linked to this study.
- Other trials for Skin and Connective Tissue DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- The SkincAIr Research App is evaluated across two non-randomized arms: (1) Clinical Image Data Collection - dermatologists in 5 countries use the Dermatologist Dataset eCRF to collect and annotate \>3,500 skin NTD images over 36 months; (2) Validation Study - 150 FHWs (50 per country, Kenya, Ethiopia, Senegal) serve as their own control across 3 consecutive phases: Phase A (12 months baseline, no AI); Phase B (6 months, AI app activated); Phase C (6 months, AI withdrawn to assess skill retention). \~750 patients enrolled per country.
- Masking
- None (open label)
- Enrolment
- 2,420 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kenya Medical Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Universidad Politecnica de Madrid, FACHHOCHSCHULE ZENTRALSCHWEIZ - HOCHSCHULE LUZERN, SHERWOOD HEALTHCARE SENEGAL SARL, King's College London, TEACUP CONSULTING SL, MTU AUSTRALO ALPHA LAB, OMODI, AGASNA, ODIEMBO ADVOCATES LLP, OEUVRES HOSPITALIERES FRANCAISES DE L'ORDRE DE MALTE, Armauer Hansen Research Institute, Ethiopia, Leprosy and Tuberculosis Relief Initiative Nigeria, UNIVERSITE CATHOLIQUE DE BUKAVU
- Responsible party
- Principal investigator, Maurice Odiere, Kenya Medical Research Institute
- Investigators
- Gustavo H Penaloza, PhD, Study chair, Polytechnic University of Madrid (UPM)Carla Rodríguez Cuesta, MEng, Study director, SHERWOOD HEALTHCARE SENEGAL SARL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07506967
- Sponsor's protocol ID
- EC grant agreement 101190743
- Other IDs
- MGAAres(2025)3881363
- Acronym
- SkincAIr
- Status last verified
- Mar 2026
- First submitted
- 27 Mar 2026
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymised clinical images and metadata collected via the Dermatologist Dataset eCRF will be made publicly available as an open dataset following project completion (M60). Individual participant data from the validation study will be available to researchers upon reasonable request, subject to data sharing agreements and ethics committee approval. Data will be stored on AWS eu-west-1 for 10 years post-study.
Publications
Yotsu RR. Integrated Management of Skin NTDs-Lessons Learned from Existing Practice and Field Research. Trop Med Infect Dis. 2018 Nov 14;3(4):120. doi: 10.3390/tropicalmed3040120.
PubMed 30441754Winkler JK, Fink C, Toberer F, Enk A, Deinlein T, Hofmann-Wellenhof R, Thomas L, Lallas A, Blum A, Stolz W, Haenssle HA. Association Between Surgical Skin Markings in Dermoscopic Images and Diagnostic Performance of a Deep Learning Convolutional Neural Network for Melanoma Recognition. JAMA Dermatol. 2019 Oct 1;155(10):1135-1141. doi: 10.1001/jamadermatol.2019.1735.
PubMed 31411641Wiese S, Elson L, Reichert F, Mambo B, Feldmeier H. Prevalence, intensity and risk factors of tungiasis in Kilifi County, Kenya: I. Results from a community-based study. PLoS Negl Trop Dis. 2017 Oct 9;11(10):e0005925. doi: 10.1371/journal.pntd.0005925. eCollection 2017 Oct.
PubMed 28991909Wangara F, Kipruto H, Ngesa O, Kayima J, Masini E, Sitienei J, Ngari F. The spatial epidemiology of leprosy in Kenya: A retrospective study. PLoS Negl Trop Dis. 2019 Apr 22;13(4):e0007329. doi: 10.1371/journal.pntd.0007329. eCollection 2019 Apr.
PubMed 31009481van Dijk NJ, Amer S, Mwiti D, Schallig HDFH, Augustijn EW. An epidemiological and spatiotemporal analysis of visceral leishmaniasis in West Pokot, Kenya, between 2018 and 2022. BMC Infect Dis. 2024 Oct 16;24(1):1169. doi: 10.1186/s12879-024-10053-4.
PubMed 39415090Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 2009 Jan 20;19(4):203-11. eCollection 2009 Jan.
PubMed 27683318Shetty VP, Pandya SS, Arora S, Capadia GD. Observations from a 'special selective drive' conducted under National Leprosy Elimination Programme in Karjat taluka and Gadchiroli district of Maharashtra. Indian J Lepr. 2009 Oct-Dec;81(4):189-93.
PubMed 20704074Schmid-Grendelmeier P, Takaoka R, Ahogo KC, Belachew WA, Brown SJ, Correia JC, Correia M, Degboe B, Dorizy-Vuong V, Faye O, Fuller LC, Grando K, Hsu C, Kayitenkore K, Lunjani N, Ly F, Mahamadou G, Manuel RCF, Kebe Dia M, Masenga EJ, Muteba Baseke C, Ouedraogo AN, Rapelanoro Rabenja F, Su J, Teclessou JN, Todd G, Taieb A. Position Statement on Atopic Dermatitis in Sub-Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2019-2028. doi: 10.1111/jdv.15972.
PubMed 31713914Schmeller W, Dzikus A. Skin diseases in children in rural Kenya: long-term results of a dermatology project within the primary health care system. Br J Dermatol. 2001 Jan;144(1):118-24.
PubMed 11167692Salinas MP, Sepulveda J, Hidalgo L, Peirano D, Morel M, Uribe P, Rotemberg V, Briones J, Mery D, Navarrete-Dechent C. A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis. NPJ Digit Med. 2024 May 14;7(1):125. doi: 10.1038/s41746-024-01103-x.
PubMed 38744955Roberts W, Lyson H, Speer C, Tovar E, Paz E, Zimlichman E. Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program. Value Health. 2026 Apr;29(4):583-588. doi: 10.1016/j.jval.2025.01.025. Epub 2025 Feb 13.
PubMed 39954854Patel RH, Foltz EA, Witkowski A, Ludzik J. Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review. Cancers (Basel). 2023 Sep 23;15(19):4694. doi: 10.3390/cancers15194694.
PubMed 37835388Ouma FF, Mulambalah CS. Persistence and Changing Distribution of Leishmaniases in Kenya Require a Paradigm Shift. J Parasitol Res. 2021 Oct 18;2021:9989581. doi: 10.1155/2021/9989581. eCollection 2021.
PubMed 34707907Ofire MO, Omanje V, Sempele I, Chami I, Gitahi PN, Njenga SM, Omondi WP. Lymphatic filariasis elimination in Kenya: Tracing the journey from 2002-2024 and pathways to achieving 2030 target. Int J Infect Dis. 2025 Mar;152:107839. doi: 10.1016/j.ijid.2025.107839. Epub 2025 Feb 8.
PubMed 39929320Odiwuor S, Muia A, Magiri C, Maes I, Kirigi G, Dujardin JC, Wasunna M, Mbuchi M, Auwera GV. Identification of Leishmania tropica from micro-foci of cutaneous leishmaniasis in the Kenyan Rift Valley. Pathog Glob Health. 2012 Jul;106(3):159-65. doi: 10.1179/2047773212Y.0000000015.
PubMed 23265373
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Detection and Management of SKIN-related negleCted Tropical Diseases Using Artificial Intelligence in Sub-saharan afRica (SkincAIr)
- ClinicalTrials.gov ID
- NCT07506967
- Acronym / sponsor ID
- SkincAIr / EC grant agreement 101190743
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer, Cutaneous Leishmaniasis, Scabies
- Keywords
- Skin-related neglected tropical diseases, Artificial Intelligence, Mobile Health, mHealth, Frontline Health Workers, Diagnostic Accuracy, Sub-Saharan Africa, Skin NTDs
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,420 participants (estimated)
- Lead sponsor
- Kenya Medical Research InstituteUniversity, hospital or other
- Collaborators
- Universidad Politecnica de Madrid, FACHHOCHSCHULE ZENTRALSCHWEIZ - HOCHSCHULE LUZERN, SHERWOOD HEALTHCARE SENEGAL SARL, King's College London, TEACUP CONSULTING SL, MTU AUSTRALO ALPHA LAB, OMODI, AGASNA, ODIEMBO ADVOCATES LLP, OEUVRES HOSPITALIERES FRANCAISES DE L'ORDRE DE MALTE, Armauer Hansen Research Institute, Ethiopia, Leprosy and Tuberculosis Relief Initiative Nigeria, UNIVERSITE CATHOLIQUE DE BUKAVU
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 28 Feb 2029 (estimated)
- Study completion
- 31 May 2030 (estimated)
- First posted
- 2 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited. Many people rely on frontline health workers (FHWs) for treatment, but these workers often lack specialized training in skin diseases, making diagnosis difficult. To address this challenge, the SkincAIr project is testing whether a mobile app powered by artificial intelligence (AI) can help FHWs improve their ability to detect Skin NTDs. The study will be conducted in two arms. In the first clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions that will be used for development and training of the AI model within the SkincAIr app before it is tested among FHWs. The second validation study arm will take place in 3 countries (Kenya, Ethiopia and Senegal), and will involve 50 FHWs and around 750 patients in each country over 24 months. During the first 12 months (Phase A), FHWs will diagnose patients using standard methods without the app, establishing baseline performance on key indicators including diagnostic accuracy, time to diagnosis, referral patterns, and cost implications of improved primary-level diagnosis. For the following 6 months (Phase B), FHWs will use the SkincAIr app with AI functionality activated to support diagnosis and enable real-time geolocated disease mapping and hotspot identification. In the final 6 months (Phase C), the app is withdrawn to assess whether FHWs retain their improved diagnostic skills. We will summarize the results using simple numbers and charts to show how often things happen and what the average results look like. Researchers will evaluate how well the app improves diagnosis by FHWs and whether FHWs retain their improved skills even after AI support is removed, by comparing their results with those of a skin specialist (dermatologist). Interviews and group discussions will be recorded, written down, organized into key ideas, and carefully reviewed using a computer program to understand the main themes. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to relevant institutional and regulatory authorities. If successful, this AI tool could boost early detection of skin diseases, enhance disease tracking, and improve healthcare in underserved areas.
Detailed description
ABSTRACT:
Skin-related Neglected Tropical Diseases (Skin NTDs) pose a significant public health challenge, affecting 1.8 billion people globally. Skin NTDs significantly affect marginalized communities due to several factors, such as lack of trained healthcare staff and diagnostic tools. Currently, due to a scarcity of dermatologists, the majority of the rural population with skin diseases is served by frontline health workers (FHWs) with limited dermatological knowledge. The low prevalence of skin NTDs further confounds their diagnosis and recognition by FHWs. Novel innovative approaches are therefore needed to build capacity and improve diagnosis for skin NTDs. Mobile health (mHealth) interventions, particularly those incorporating artificial intelligence (AI), offer a promising solution to enhance the diagnostic capabilities of FHWs. The SkincAIr project aims to evaluate whether introducing a mobile app with AI functionality can improve the diagnostic accuracy (sensitivity and specificity) of FHWs in detecting skin NTDs, and to determine their retention of improved diagnostic skills after the AI assistance is removed, indicating potential capacity building and sustained improvement in healthcare delivery. In the clinical image data collection arm (36 months), dermatologists in 5 countries (Kenya, Ethiopia, Senegal, Democratic Republic of Congo and Nigeria) will collect images of skin NTD and other skin conditions (Image data collection phase) that will be used for training and development of the SkincAIr app, before it is evaluated among FHWs during the 24-month validation study. The validation study arm for the app will involve a within-subjects longitudinal design which will enroll 50 FHWs and will recruit about 750 patients with skin complaints from areas with high burden of skin NTDs in each of 3 countries (Kenya, Ethiopia, Senegal) over a 24-month validation study period. Data will be analyzed using R and Python, with descriptive statistics (frequency, central tendency, and dispersion) summarized in tables and charts. Diagnostic accuracy of FHWs before and after app introduction will be evaluated using sensitivity, specificity, predictive values, and percent agreement with a dermatologist. Qualitative data from interviews and FGDs will be audio-recorded, transcribed, coded, and thematically analyzed using Atlas.ti Version 7. Study findings will be shared with National Ministries of Health, presented at local and international conferences, and reported to IRBs and regulatory authorities. It is envisaged that the app will improve the diagnostic accuracy of FHWs in early detection of skin NTDs and will facilitate real-time epidemiological surveillance, contributing to improved disease mapping and hotspot identification.
INTRODUCTION/BACKGROUND:
Skin-related Neglected Tropical Diseases (MDPI, 2019) (skin NTDs) such as leprosy, Buruli ulcer, yaws (endemic treponematosis), cutaneous leishmaniasis, chromoblastomycosis, mycetoma, scabies, tungiasis, Post Kala-azar Dermal Leishmaniasis (PKDL), lymphatic filariasis, onchocerciasis, podoconiosis and sporotrichosis pose a significant public health challenge, affecting 1.8 billion people globally at any given moment (WHO, 2023). Particularly in sub-Saharan Africa (SSA), these diseases are highly prevalent and are linked to substantial health inequities, predominantly impacting marginalized communities (Kariuki et al. 2023). Kenya for instance has a significant burden of Skin NTDs, including Lymphatic filariasis at the Coastal region (Njenga et al. 2017; Ofire et al. 2025), Mycetoma in Turkana (Colom et al. 2023), Leishmaniasis in Rift Valley and Eastern parts (Baringo, Naivasha/Gilgil, Laikipia, Samburu, Nakuru, Meru, West Pokot, Elgeyo Marakwet, Isiolo, Nyandarua, and Marsabit) (Ngere et al. 2020; van Dijk et al. 2024), Tungiasis (Elson et al. 2019; Nyangacha et al. 2019) and Scabies (Schmeller and Dzikus, 2001; Mbogori 2014; Macharia et al. 2024) that have a wide distribution across the country and some pockets of cases of Leprosy in Kwale, Kilifi, Kisumu, Siaya, Homabay and Busia counties (Kenya NTLLD Program Annual Report, 2014; Wangara et al. 2019).
The prevalence of these diseases is exacerbated by factors such as poverty and a lack of adequate healthcare resources, notably insufficiently trained staff for effective management of skin NTDs (Ochola et al. 2021). The stigma surrounding skin NTDs, entrenched in societal and economic contexts, leads to isolation and discrimination, discouraging diagnosis or treatment, which in turn exacerbates disease spread and complicates control and elimination efforts, creating a self-perpetuating cycle of challenges. A high proportion of NTDs have major skin manifestations. Therefore, examination of the skin serves as an opportunity to identify multiple NTDs in a single intervention. The integrative approach, recommended by the World Health Organization (WHO) (https://www.who.int/activities/promoting-the-integrated-approach-to-skin-related-neglected-tropical-diseases), results in enhanced case detection and increased efficiency through sharing of resources and expanded programme coverage. However, there is a major barrier to the integration of skin NTD interventions: the lack of dermatologists (Schmid-Grendelmeier et al. 2019) (one dermatologist for 1-2 million inhabitants) and adequately trained healthcare staff. Currently, the majority of the rural population with skin diseases is served by frontline health workers (FHWs) with limited dermatological knowledge (Mieras et al. 2018). This challenge is further confounded by the low prevalence of skin-related NTDs, which makes them difficult to be recognized by FHWs (Mieras et al. 2018; Hotez et al. 2009). As skin NTDs rely mostly on clinical diagnosis, lack of adequate training of FHWs jeopardizes disease control programs and the attainment of the overall 2021-2030 WHO NTD roadmap target to reduce morbidity, disability and the psychosocial impact of skin NTDs by 2030. Novel innovative approaches are needed to build capacity and improve diagnosis for skin NTDs to realize the 2030 goals. In this regard, Artificial Intelligence (AI) now provides an unprecedented opportunity to use advances in medical imaging applied to the skin to tackle current barriers in the diagnosis and management of skin NTDs in SSA.
Existing AI models in dermatology often focus on diseases prevalent in developed countries and rely on homogeneous datasets, leading to models that do not generalize well to diverse populations. They typically use internal validation methods, which are insufficient for real-world deployment where models encounter varied data sources (Daneshjou et al. 2021). Whereas AI-powered algorithms have demonstrated diagnostic accuracy similar to expert clinicians in high-resource settings (Salinas et al. 2024), very few studies have explored the use of AI-powered apps for diagnosing skin NTDs in low-resource settings in SSA. This is due to the novelty of the technology which contributes to the scarcity of such research. The WHO NTD-led Global Initiative discusses progress, challenges, gaps and solutions in developing and implementing artificial augmented intelligence-based apps as a capacity building and monitoring tool for skin NTDs and selected common skin conditions in resource-limited settings. Recently, the WHO incorporated two online AI algorithms that intend to classify 12 skin NTDS and 24 common skin conditions (Quilter et al. 2024) into the WHO Skin NTDs app (mainly built as a repository of educational resources and training materials, which adhere to WHO guidelines). While the app aims to improve capacity building through AI, its "real-world" impact on disease management is still not available and upcoming studies will determine its utility. The performance of AI-algorithms is also limited by the availability of images datasets. In the AI4Leprosy study conducted in 2022 at the Brazil leprosy national referral center, although the convolutional neural networks (CNN)-based AI algorithm could contribute to the diagnosis of leprosy with high classification accuracy (90%) (AI4Leprosy), to the best of our knowledge, this has not been validated in a low-resource setting with lack of highly specialized staff. Further afield, while the technology's performance is increasingly being validated in dermatological conditions such as melanoma and other skin cancers (Patel et al. 2023), the direct evidence for its efficacy in diagnosing skin-NTDs remains limited. Overall, while these studies and initiatives demonstrate the potential of AI-powered diagnostic tools, evidence specific to their use for skin NTDs in low-resource settings is still emerging.
Our proposed validation study aims to address the aforementioned gaps by evaluating the diagnostic accuracy of an AI-powered app in diagnosing skin NTDs in Kenya, Ethiopia and Senegal, providing critical insights into its practical utility and impact on clinical practice in these settings. The intervention is the SkincAIr Research App, a unified mobile platform containing three role-specific modules: a Dermatologist Dataset eCRF for structured image collection by dermatologists across 5 countries; an FHW eCRF for clinical data collection and case documentation across all 3 study phases; and the SkincAIr Detection App - an AI-powered diagnostic decision-support feature embedded within the FHW eCRF, activated exclusively during Phase B (6 months), and withdrawn during Phase C to assess retention of improved diagnostic skills. The study measures: (SO1) diagnostic performance of FHWs with and without the app, including early detection rate, diagnostic accuracy, sensitivity and specificity against a dermatologist reference standard; (SO2) dataset quality including number, geographic diversity and image quality; (SO3) reduction in diagnostic delay; (SO4) epidemiological surveillance indicators including DHIS2 integration, case confirmation ratio and hotspot identification; (SO5) FHW knowledge gain and user satisfaction. Cost-effectiveness is assessed through primary vs secondary care cost comparison and ICER calculation.
This clinical study will provide vital data to assess the practical utility of AI in improving diagnostic accuracy and speed among non-specialist health workers. By leveraging AI and mobile technology, we can equip FHWs in low-resource settings with tools to quickly detect and manage skin NTDs.
Justification for the Study:
Neglected tropical diseases (NTDs) affect over one billion people globally, with skin NTDs such as leprosy, cutaneous leishmaniasis, and onchocerciasis contributing significantly to morbidity, disability, and stigma in affected populations. Early detection and treatment are crucial to prevent complications, reduce transmission, and improve patient outcomes. In resource-limited settings like Kenya, Ethiopia, Senegal, Nigeria and the Democratic Republic of the Congo, FHWs are often the first point of contact for patients with skin conditions. However, FHWs typically lack specialized training in dermatology, leading to misdiagnosis or delayed diagnosis of skin NTDs. Mobile health (mHealth) interventions, particularly those incorporating AI, offer a promising solution to enhance the diagnostic capabilities of FHWs. The SkincAIr project aims to evaluate whether introducing a mobile app with AI functionality can improve the diagnostic accuracy of FHWs in detecting skin NTDs. Additionally, the study seeks to determine if FHWs retain improved diagnostic skills after the AI assistance is removed, indicating potential capacity building and sustained improvement in healthcare delivery. Our project transcends the twin limitations of lack of specialized training in dermatology and availability of images datasets by collecting real clinical data from multiple geographic locations within Low-and Middle-Income Countries (LMICs), ensuring that our models are trained and externally validated on diverse datasets representative of the target populations. Inclusion of Kenya, Ethiopia, Senegal, Nigeria and the Democratic Republic of the Congo will contribute to the diversity of images that are representative of the Skin NTDs endemic in multiple geographic locations in sub-Saharan Africa. As these locations present unique challenges, including limited healthcare infrastructure and varying disease presentations, the proposed study is crucial in bridging this gap. We will implement a controlled image acquisition protocol to standardize data collection, minimizing the risk of shortcut learning - where models might rely on irrelevant features due to spurious correlations (Winkler et al. 2019). By integrating multimodal data, including clinical parameters, and ensuring robustness to missing data, our models will offer more accurate and personalized diagnostic and predictive capabilities.
Null Hypothesis:
The use of the SkincAIr AI-powered mobile application will not improve the diagnostic accuracy (sensitivity and specificity) of FHWs in detecting skin-NTDs compared to their baseline performance without the app.
General Objective:
To develop an AI supported diagnostic tool for skin NTDs (SkincAIr) and test its performance and impact among frontline health workers (FHWs) in detecting select skin NTDs.
Specific Objectives:
- To collect image data for skin NTDs and other skin conditions by dermatologists/dermatology officers or other officers trained on skin NTDS to be used in the training and development of the SkincAIr app.
- To quantify the impact of the SkincAIr mobile application on the diagnostic accuracy (sensitivity and specificity) of frontline health workers (FHWs) in identifying skin-neglected tropical diseases (skin-NTDs) and other skin conditions.
- To measure the impact of SkincAIr-assisted diagnosis on key clinical and operational metrics:
- Time to diagnosis from first visit - How long it takes for a patient to receive a diagnosis, from the time they first present to a healthcare provider
- Time from initial presentation to definitive diagnosis - the time from any initial contact (perhaps community level or first clinic) to the final confirmed diagnosis by a specialist
- Reduction in treatment initiation delays
- Changes in referral patterns to specialized centers - Changes in how often and how appropriately patients are referred to specialists or higher centers
- Cost savings in secondary care attributable to enhanced primary diagnosis (early and accurate diagnoses by FHWs)
- New hotspots of suspected or confirmed skin NTDs during the project period (up to M60).
- To evaluate the sustainability of improved diagnostic skills among FHWs following the withdrawal of AI assistance.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The SkincAIr Research App is evaluated across two non-randomized arms: (1) Clinical Image Data Collection - dermatologists in 5 countries use the Dermatologist Dataset eCRF to collect and annotate >3,500 skin NTD images over 36 months; (2) Validation Study - 150 FHWs (50 per country, Kenya, Ethiopia, Senegal) serve as their own control across 3 consecutive phases: Phase A (12 months baseline, no AI); Phase B (6 months, AI app activated); Phase C (6 months, AI withdrawn to assess skill retention). ~750 patients enrolled per country.
| Arm | Type | Receives |
|---|---|---|
| Clinical Image Data Collection | Other | Device: A mobile app with AI functionality for diagnosing skin-related NTDsDermatologists in 5 countries (Kenya, Ethiopia, Senegal, Nigeria and DRC) use the Dermatologist Dataset eCRF module of the SkincAIr Research App to capture and annotate high-quality clinical images of skin NTDs and other skin conditions during routine clinical activity (M12-M48, 36 months). Structured metadata including disease type, body site, age group, severity and geographic location are recorded alongside each image. Collected images are used exclusively to train and develop the SkincAIr AI model prior to its validation among frontline health workers. Target: >3,500 high-quality annotated images of skin NTDs across 11 disease categories in 5 countries (KPI 2.1). |
| SkincAIr Validation Study - Frontline Health Workers | Experimental | Device: A mobile app with AI functionality for diagnosing skin-related NTDs50 frontline health workers (FHWs) per country (Kenya, Ethiopia, Senegal) and ~750 patients with skin complaints per country participate in a 24-month within-subjects validation study using the SkincAIr Research App. FHWs complete 3 consecutive phases: Phase A (M22-M33, 12 months): baseline data collection using standard diagnostic methods without AI support, using the FHW eCRF only; Phase B (M34-M39, 6 months): AI-assisted diagnosis using the SkincAIr Detection App embedded in the FHW eCRF, activated exclusively during this phase; Phase C (M40-M45, 6 months): AI support withdrawn to assess retention of improved diagnostic skills. Each FHW serves as their own control. A reference dermatologist independently evaluates each patient to provide the gold standard diagnosis. |
Who may qualify
- Ages
- 0 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (21 listed)
- o Must be working as a FHW at one of the selected health centers at the time of the validation study.
- o Willing to provide written informed consent to participate in the study.
- o Willing and able to use a smartphone during the study.
- o Patients presenting to participating health centres with symptoms suggestive of skin-NTDs (e.g., visible skin lesions, nodules, ulcers) but have not been diagnosed by a specialist for that specific skin condition.
- o Patients are able to follow study instructions and attend necessary follow-up appointments.
Key exclusion criteria (32 listed)
- o FHWs with formal education or extensive experience in dermatology.
- Patients with Skin complaints Size
- ● Total Patients: ~750 patients Age Group
- o Justification: Skin-NTDs affect individuals of all ages; including all age groups enhances the generalizability of the findings and assesses the app's effectiveness across the lifespan.
- Sex Distribution
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A mobile app with AI functionality for diagnosing skin-related NTDsAlso: SkincAIr Detection AppThe SkincAIr Research App is a unified mobile platform (Android, offline-capable) containing three role-specific modules: (1) Dermatologist Dataset eCRF - used by dermatologists in 5 countries (M12-M48) to capture and annotate high-quality clinical images of skin NTDs for AI model development; (2) FHW eCRF - used by frontline health workers (FHWs) in 3 countries (M22-M45) to document clinical assessments with and without AI support; (3) SkincAIr Detection App - an AI-powered diagnostic decision-support feature embedded within the FHW eCRF, activated exclusively during Phase B (6 months), providing image-based diagnostic suggestions to assist FHWs in identifying skin NTDs. The SkincAIr Detection App is the primary intervention under validation. If proven effective, it is intended for adoption by National Ministries of Health, integration into national Health Information Systems (DHIS2), and scale-up across sub-Saharan Africa. | Device | Clinical Image Data Collection, SkincAIr Validation Study - Frontline Health Workers |
Primary outcome
FHW Diagnostic Accuracy Improvement (FHW-DAI)
Time frame: Month 22 through Month 45
Percentage improvement in diagnostic accuracy of frontline health workers (FHWs) when using the SkincAIr Detection App compared to baseline performance without the app. Diagnostic accuracy is measured by comparing FHW diagnoses against the reference standard diagnosis established independently by a co-located dermatologist for each patient case. A minimum improvement of 15% (KPI 1.3) is required to demonstrate clinical utility of the app. Measured across all 3 study phases: Phase A (baseline, no app, M22-M33); Phase B (app active, M34-M39); Phase C (app withdrawn, M40-M45).
12 secondary outcomes
Early Detection Rate of Skin NTDs by FHWs (KPI 1.1)
Time frame: 22 through Month 39
Time Reduction from FHW Suspicion to Diagnostic Confirmation (KPI 1.2)
Time frame: Month 22 through Month 45
Sensitivity of FHW Diagnosis for Skin NTDs (KPI 1.4)
Time frame: Month 22 through Month 45
Specificity of FHW Diagnosis for Skin NTDs (KPI 1.5)
Time frame: Month 22 through Month 45
Diagnostic Delay Reduction from First Healthcare Contact to Confirmation (KPI 3.1)
Time frame: Month 22 through Month 45
FHW Diagnostic Knowledge Gain and Retention (KPI 5.1)
Time frame: Month 33 through Month 45
User Education Satisfaction Index (UESI) (KPI 5.2)
Time frame: Month 34 through Month 39
Epidemiological Surveillance - Subjects Integrated into DHIS2 (KPI 4.1)
Time frame: Month 22 through Month 60
Case Confirmation Ratio (CCR) (KPI 4.2)
Time frame: Month 22 through Month 45
Response Time to Hotspot Identification (KPI 4.3)
Time frame: Month 22 through Month 60
New Skin NTD Hotspots Identified (KPI 4.4)
Time frame: Month 12 through Month 60
Cost-Effectiveness of AI-Assisted Primary Diagnosis
Time frame: Month 22 through Month 45
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
- Background: PubMed 30441754Yotsu RR. Integrated Management of Skin NTDs-Lessons Learned from Existing Practice and Field Research. Trop Med Infect Dis. 2018 Nov 14;3(4):120. doi: 10.3390/tropicalmed3040120.
- Background: PubMed 31411641Winkler JK, Fink C, Toberer F, Enk A, Deinlein T, Hofmann-Wellenhof R, Thomas L, Lallas A, Blum A, Stolz W, Haenssle HA. Association Between Surgical Skin Markings in Dermoscopic Images and Diagnostic Performance of a Deep Learning Convolutional Neural Network for Melanoma Recognition. JAMA Dermatol. 2019 Oct 1;155(10):1135-1141. doi: 10.1001/jamadermatol.2019.1735.
- Background: PubMed 28991909Wiese S, Elson L, Reichert F, Mambo B, Feldmeier H. Prevalence, intensity and risk factors of tungiasis in Kilifi County, Kenya: I. Results from a community-based study. PLoS Negl Trop Dis. 2017 Oct 9;11(10):e0005925. doi: 10.1371/journal.pntd.0005925. eCollection 2017 Oct.
- Background: PubMed 31009481Wangara F, Kipruto H, Ngesa O, Kayima J, Masini E, Sitienei J, Ngari F. The spatial epidemiology of leprosy in Kenya: A retrospective study. PLoS Negl Trop Dis. 2019 Apr 22;13(4):e0007329. doi: 10.1371/journal.pntd.0007329. eCollection 2019 Apr.
- Background: PubMed 39415090van Dijk NJ, Amer S, Mwiti D, Schallig HDFH, Augustijn EW. An epidemiological and spatiotemporal analysis of visceral leishmaniasis in West Pokot, Kenya, between 2018 and 2022. BMC Infect Dis. 2024 Oct 16;24(1):1169. doi: 10.1186/s12879-024-10053-4.
- Background: PubMed 27683318Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 2009 Jan 20;19(4):203-11. eCollection 2009 Jan.
- Background: PubMed 20704074Shetty VP, Pandya SS, Arora S, Capadia GD. Observations from a 'special selective drive' conducted under National Leprosy Elimination Programme in Karjat taluka and Gadchiroli district of Maharashtra. Indian J Lepr. 2009 Oct-Dec;81(4):189-93.
- Background: PubMed 31713914Schmid-Grendelmeier P, Takaoka R, Ahogo KC, Belachew WA, Brown SJ, Correia JC, Correia M, Degboe B, Dorizy-Vuong V, Faye O, Fuller LC, Grando K, Hsu C, Kayitenkore K, Lunjani N, Ly F, Mahamadou G, Manuel RCF, Kebe Dia M, Masenga EJ, Muteba Baseke C, Ouedraogo AN, Rapelanoro Rabenja F, Su J, Teclessou JN, Todd G, Taieb A. Position Statement on Atopic Dermatitis in Sub-Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2019-2028. doi: 10.1111/jdv.15972.
- Background: PubMed 11167692Schmeller W, Dzikus A. Skin diseases in children in rural Kenya: long-term results of a dermatology project within the primary health care system. Br J Dermatol. 2001 Jan;144(1):118-24.
- Background: PubMed 38744955Salinas MP, Sepulveda J, Hidalgo L, Peirano D, Morel M, Uribe P, Rotemberg V, Briones J, Mery D, Navarrete-Dechent C. A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis. NPJ Digit Med. 2024 May 14;7(1):125. doi: 10.1038/s41746-024-01103-x.
- Background: PubMed 39954854Roberts W, Lyson H, Speer C, Tovar E, Paz E, Zimlichman E. Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program. Value Health. 2026 Apr;29(4):583-588. doi: 10.1016/j.jval.2025.01.025. Epub 2025 Feb 13.
- Background: PubMed 37835388Patel RH, Foltz EA, Witkowski A, Ludzik J. Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review. Cancers (Basel). 2023 Sep 23;15(19):4694. doi: 10.3390/cancers15194694.
- The WHO Skin NTD mobile application - a paradigm shift in leprosy diagnosis through Artificial Intelligence?Link provided by the sponsor.
- The Burden of Neglected Tropical Diseases in Sub-Saharan AfricaLink provided by the sponsor.
- Kenya National Tuberculosis Leprosy and Lung Disease Program Annual Report, 2014Link provided by the sponsor.
- Awareness, Attitudes, Perceptions and Practices of Scabies Infestation among Caregivers of Children under 5 Years of Age in Villages of Kwale County, KenyaLink provided by the sponsor.
- Mbogori M. 2014 (Thesis)Link provided by the sponsor.
- Wayne W. Daniel, Chad L. Cross, Biostatistics: A Foundation for Analysis in the Health Sciences, 2013, page 191Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymised clinical images and metadata collected via the Dermatologist Dataset eCRF will be made publicly available as an open dataset following project completion (M60). Individual participant data from the validation study will be available to researchers upon reasonable request, subject to data sharing agreements and ethics committee approval. Data will be stored on AWS eu-west-1 for 10 years post-study.
Related trials for Skin and Connective Tissue Diseases
RecruitingPhase 2
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Hidradenitis Suppurativa (HS)
RecruitingPhase 2
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
RecruitingPhase 2
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN)
Not yet recruitingPhase 1/2
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
Sanfilippo Syndrome (MPS III)
Enrolling by invitationPhase 3
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gustavo H Penaloza, PhD study chair
Polytechnic University of Madrid (UPM)
Carla Rodríguez Cuesta, MEng study director
SHERWOOD HEALTHCARE SENEGAL SARL
5 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing A mobile app with AI functionality for diagnosing skin-related NTDs in people with Skin and Connective Tissue Diseases and Neglected Tropical Diseases, run by Kenya Medical Research Institute at 5 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Democratic Republic of the Congo, Ethiopia, Kenya, Nigeria, Senegal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maurice R Odiere, PhD (254721845777, Modiere@kemri.go.ke), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FHW Diagnostic Accuracy Improvement (FHW-DAI) (time frame: Month 22 through Month 45). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07506967, which also lists 30 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026; AzTrials last refreshed its copy on 26 Oct 2026.